Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
03 June 2020Website:
http://pliantrx.comNext earnings report:
08 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Mon, 28 Oct 2024 22:16:30 GMTDividend
Analysts recommendations
Institutional Ownership
PLRX Latest News
Former Bristol Myers Squibb Global Medical Affairs Lead brings over 25 years of experience to Pliant SOUTH SAN FRANCISCO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the appointment of Gary Palmer, M.D.
SOUTH SAN FRANCISCO, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced four upcoming presentations at the European Respiratory Society (ERS) International Congress 2024. The Congress will take place in Vienna, Austria from September 7 - 11, 2024.
SOUTH SAN FRANCISCO, June 13, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the appointment of Steve Krognes to its Board of Directors.
SOUTH SAN FRANCISCO, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced two poster presentations, including a late-breaker, were presented at the European Association for the Study of the Liver (EASL) International Liver Congress™ being held June 5-8, 2024.
SOUTH SAN FRANCISCO, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced that the Company presented clinical data and preclinical data of bexotegrast (PLN-74809) this week as part of the American Thoracic Society (ATS) 2024 International Conference, held from May 17-22, 2024.
Pliant Therapeutics, Inc. (PLRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pliant Therapeutics (PLRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Shares of Pliant Therapeutics, Inc. PLRX gained 14.3% on Sep 26 after the company announced that its mid-stage study on lead pipeline candidate bexotegrast was successful.
Pliant Therapeutics Inc. shares PLRX, -2.86% gained 23% premarket on Tuesday after the company released results from a trial of bexotegrast, a treatment for a chronic liver disease. The trial met its primary and secondary goals, and bexotegrast was well tolerated over a 12-week treatment period in patients with primary sclerosing cholangitis (PSC) and suspected liver fibrosis, the company said in a release.
Pliant Therapeutics is a clinical-stage biotech. The company said it has enough cash to fund operations through the second half of 2026.
What type of business is Pliant Therapeutics?
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
What sector is Pliant Therapeutics in?
Pliant Therapeutics is in the Healthcare sector
What industry is Pliant Therapeutics in?
Pliant Therapeutics is in the Biotechnology industry
What country is Pliant Therapeutics from?
Pliant Therapeutics is headquartered in United States
When did Pliant Therapeutics go public?
Pliant Therapeutics initial public offering (IPO) was on 03 June 2020
What is Pliant Therapeutics website?
https://pliantrx.com
Is Pliant Therapeutics in the S&P 500?
No, Pliant Therapeutics is not included in the S&P 500 index
Is Pliant Therapeutics in the NASDAQ 100?
No, Pliant Therapeutics is not included in the NASDAQ 100 index
Is Pliant Therapeutics in the Dow Jones?
No, Pliant Therapeutics is not included in the Dow Jones index
When was Pliant Therapeutics the previous earnings report?
No data
When does Pliant Therapeutics earnings report?
The next expected earnings date for Pliant Therapeutics is 08 November 2024